Drug
D0959 | idazoxan
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 20.64±7.46 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | human | HepG2 | MMP assay | Negative | IC50 | 163 | ||
| MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | oral | 85mg/kg (85mg/kg) | European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 25, Pg. 557, 1990. | |
| (+-)-2-(1,4-Benzodioxan-2-yl)-2-imidazoline | 1H-Imidazole, 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)- | 2-(1,4-benzodioxan-2-yl)imidazoline |
| 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole | 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole | 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-1H-imidazole |
| 79944-58-4 | A839791 | AB00489883-09 |
| AB00489883_10 | AB00514632 | AKOS015915004 |
| API0007263 | BDBM50019848 | BPBio1_000916 |
| BRD-A18696154-003-03-6 | BRD-A18696154-003-14-3; | BSPBio_000832 |
| C10968 | CAS-79944-58-4 | CCG-204739 |
| CHEBI:5862 | CHEMBL10316 | DB12551 |
| DSSTox_CID_25161 | DSSTox_GSID_45161 | DSSTox_RID_80711 |
| DTXSID6045161 | FT-0655996 | HMS2089E14 |
| HPMRFMKYPGXPEP-UHFFFAOYSA-N | IDAZOXAN | Idazoxan [BAN:INN] |
| Idazoxan [INN:BAN] | Idazoxane | Idazoxane [French] |
| Idazoxano | Idazoxano [Spanish] | Idazoxanum |
| Idazoxanum [Latin] | L000808 | LS-78447 |
| Lopac0_000652 | NCGC00015560-04 | NCGC00015560-05 |
| NCGC00015560-06 | NCGC00015560-08 | NCGC00015560-09 |
| NCGC00015560-10 | NCGC00015560-12 | NCGC00024794-03 |
| NCGC00024794-04 | Prestwick0_000926 | Prestwick1_000926 |
| Prestwick2_000926 | Prestwick3_000926 | Q5987770 |
| RX-781094 | SBI-0050632.P002 | SCHEMBL114731 |
| SPBio_003011 | Tox21 110173 | Tox21_110173 |
| Tox21_110173_1 | US8633208, Idazoxan | idasoxan |